The Malaria DREAM Challenge is open to anyone interested in developing computational models to address problems in malaria. The goal is to predict the changing biology of Artemisinin-resistant malaria parasites.
The Johns Hopkins Bloomberg School of Public Health hosts this one-day scientific symposium on April 25th, 2019. It includes presentations from leading researchers, a lunch-time poster session and opportunities for trainees to interact with established malaria researchers.
The Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global Fund) has opened a request for proposals (RFP) in Innovative Finance Mechanism for Malaria Elimination. The deadline for applications is April 17th 2019.
Which mosquitoes transmit the parasites responsible for malaria? Is the Asian tiger mosquito vector of the Zika virus? How is the transmission from vectors to humans and from humans to vector? Here are some of the questions that will find answers in the MOOC Pasteur "Medical Entomology", starting March 18th, 2019.
WHO is undertaking a consultative process to solicit inputs into a prioritization framework for the research and development (R&D) of malaria health products. A draft report “Analysis of Malaria R&D Priorities” identifies five key challenges that represent threats or barriers to achieving the WHO Global Technical Strategy for Malaria 2016–2030 goals. This early copy of the report is being shared at a time when WHO is exploring how best to guide and support the development of priority solutions to meet public health needs.
The MESA Alliance is set to co-host an invite-only scientific symposium entitled, “Innovate for Collective Impact to End Malaria,” on Friday, January 11, 2019, at the National Academy of Sciences in Washington, DC, USA. Its core objective is to frame a response to the 2018 World Malaria Report and to develop innovative approaches to collectively bridge critical issues in malaria eradication spanning research, financing, and implementation.
Another MESA grantee has finalised its projects and shared the findings: the MESA-funded IVERMAL Study, a randomised, double-blind, placebo-controlled trial conducted in Kenya and led by the Liverpool School of Tropical Medicine (LSTM) has produced new evidence that supports the use of ivermectin as a tool for malaria elimination.